Boston Scientific Investors Get May 4 Deadline to Seek Lead Role in Securities Suit

Overview

• Investors in Boston Scientific now have until May 4, 2026 to ask a court to serve as lead plaintiff in a newly filed securities class action.
• The case covers stock bought from July 23, 2025 to February 3, 2026 and focuses on the U.S. electrophysiology business, which provides tools to treat irregular heart rhythms.
• Filings allege management praised an unsustainable growth rate, faced new rivals that cut into U.S. market share, and raised full‑year targets without a sound basis.
• Plaintiff notices say a net income miss and weak guidance for the first half of fiscal 2026 revealed these issues and caused investor losses.
• Rosen Law Firm and Glancy Prongay Wolke & Rotter are recruiting class members, and they note the case is at an early stage with no class yet certified.